Esperion Therapeutics, Inc.
LSE: 0IIM.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Sheldon L. Koenig
- Employees
- 304
- Headquarters
- Ann Arbor, United States
- IPO year
- 2018
- Market cap
- $653.2M
- Website
- https://www.esperion.com
Loading 0IIM…
Loading profile data…Frequently asked questions about 0IIM
What does Esperion Therapeutics, Inc. (0IIM.L) do?
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
Where does 0IIM.L trade?
Esperion Therapeutics, Inc. (0IIM.L) trades on the London Stock Exchange.
What sector is 0IIM.L in?
Esperion Therapeutics, Inc. (0IIM.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Esperion Therapeutics, Inc.?
Sheldon L. Koenig is the chief executive officer of Esperion Therapeutics, Inc. (0IIM.L).
Where is Esperion Therapeutics, Inc. headquartered?
Esperion Therapeutics, Inc. is headquartered in United States.
Does 0IIM.L pay a dividend?
Esperion Therapeutics, Inc. (0IIM.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IIM.L go public?
Esperion Therapeutics, Inc. (0IIM.L) completed its initial public offering in 2018.